Skip to main content
. 2017 Jun 12;10:135–143. doi: 10.2147/IJNRD.S105771

Table 1.

DOACs in patients with advanced CKD

Dosage Comment
Direct factor Xa inhibitors
Apixaban eGFR 30–49 mL/min: 2×5 mg/d
If >1 additional criteria age >80 years, body weight <60 kg, creatinine >1.5 mg/dL: 2×2.5 mg/d
Renal elimination 27%
Rivaroxaban eGFR 30–49 mL/min: 10 mg/d Renal elimination 33%
Edoxaban eGFR 15–50 mL/min: 30 mg/d Renal elimination 50%, not recommended if eGFR <30 mL/min
Direct thrombin inhibitors
Dabigatran eGFR >60 mL/min: 2×150 mg/d Not recommended if eGFR <60 mL/min; contraindicated if eGFR<30 mL/min; renal elimination 80%

Note: Most data are derived from studies in patients with AF. The dosages for patients with advanced CKD and venous thromboembolism or AF are similar.31,3538,40,41,68,75,76

Abbreviations: AF, atrial fibrillation; CKD, chronic kidney disease; DOACs, direct oral anticoagulants; eGFR, estimated glomerular filtration rate.